ライフサイエンスコーパス: alpha 1-acid glycoprotein

1 Ser or Thr and at the carbohydrate sites of alpha 1-acid glycoprotein.

2 ich correlated with plasma concentrations of alpha-1 acid glycoprotein.

3 high binding affinity of UCN-01 to the human alpha-1-acid glycoprotein.

4 um lipopolysaccharide binding protein (LBP), Alpha-1-acid glycoprotein 1 (ORM-1), tumor necrosis fact

5 ic acid phosphatase (ACPP), clusterin (CLU), alpha-1-acid glycoprotein 1 (ORM1), and CD antigen 97 (C

6 expression changes in beta-2-glycoprotein 1, alpha-1-acid glycoprotein 1, alpha-2-macroglobulin, comp

7 glycoproteins, beta-2-glycoprotein 1 (APOH), alpha-1-acid glycoprotein 2 (ORM2), and complement C3 (C

8 We studied inflammatory blood proteins (Alpha-1-acid glycoprotein-A1AG1; Albumin; Cystatin C; C-

9 alin-like prostaglandin D synthase (L-PGDS), alpha(1) -acid glycoprotein (AAG), transferrin (TF), cer

10 omplexity in the carbohydrate composition of alpha(1)-acid glycoprotein (AAG) makes it an ideal model

11 A new method for the immobilization of alpha(1)-acid glycoprotein (AGP) in high-performance liq

12 At baseline, alpha(1)-acid glycoprotein (AGP) was elevated in 42.9% a

13 ned by radioimmunoassays, and transthyretin, alpha(1)-acid glycoprotein (AGP), alpha(1)-antichymotryp

14 roteins (APPs), C-reactive protein (CRP) and alpha(1)-acid glycoprotein (AGP), individually and in co

15 We examined the associations between serum alpha(1)-acid glycoprotein (AGP), serum C-reactive prote

16 by binding to the acute phase serum protein, alpha(1)-acid glycoprotein (AGP).

17 primarily responsible for drug binding, the alpha(1)-acid-glycoprotein (AGP) and human serum albumin

18 ed at a micro liquid-liquid interface, using alpha(1)-acid-glycoprotein (AGP) as a chiral acute phase

19 tuin, asialofetuin, IgG, ribonuclease B, and alpha-1 acid glycoprotein (AGP) by PGC-LC-MS.

20 ere was a positive correlation between serum alpha-1 acid glycoprotein (AGP) concentration and plasma

21 determine whether glycosylation patterns of alpha-1 acid glycoprotein (AGP) could be used as a marke

22 copeptides derived from bovine fetuin, human alpha-1 acid glycoprotein (AGP), and human erythropoieti

23 Biomarkers of inflammation (alpha-1-acid glycoprotein (AGP) and C-reactive protein (

24 alpha-1-Acid glycoprotein (AGP) and transferrin (Tf) are

25 ory response of C-reactive protein (CRP) and alpha-1-acid glycoprotein (AGP) by infection status, mod

26 tive protein (CRP) concentrations >5 mg/L or alpha-1-acid glycoprotein (AGP) concentrations >1 g/L, 2

27 tive protein (CRP) concentrations >5 mg/L or alpha-1-acid glycoprotein (AGP) concentrations >1 g/L, 2

28 tive protein (CRP) concentrations >5 mg/L or alpha-1-acid glycoprotein (AGP) concentrations >1 g/L; 3

29 and detecting purified as well as endogenous alpha-1-acid glycoprotein (AGP) in human plasma.

30 between PZC and C-reactive protein (CRP) or alpha-1-acid glycoprotein (AGP) was observed: 1) exclude

31 iary disorder whose pathogenesis may involve alpha-1-acid glycoprotein (AGP), an acute phase inflamma

32 ions between inflammation biomarkers, CRP or alpha-1-acid glycoprotein (AGP), and serum 25(OH)D conce

33 biomarkers such as C-reactive protein (CRP), alpha-1-acid glycoprotein (AGP), ferritin, and retinol.

34 ectin-3 (hGal-3C) and three human serum GPs, alpha-1-acid glycoprotein (AGP), haptoglobin phenotype 1

35 Concentrations of C-reactive protein (CRP), alpha-1-acid glycoprotein (AGP), soluble endoglin (sEng)

36 te phase proteins (C-reactive protein [CRP], alpha-1-acid glycoprotein [AGP]) and biomarkers of MN st

37 Plasma C-reactive protein, alpha(1)-acid glycoprotein, alpha(1)-antitrypsin, haptog

38 red the relation between C-reactive protein, alpha 1 acid glycoprotein and albumin, an acute phase pr

39 There was no relation between alpha 1 acid glycoprotein and either myocardial infarcti

40 Human alpha-1 acid glycoprotein and a therapeutic monoclonal a

41 garded as being random, we have found, using alpha-1-acid glycoprotein and antitrypsin as model syste

42 ntly labeled proteins, ubiquitin, myoglobin, alpha-1-acid glycoprotein and lysozyme, were incubated w

43 erization of the highly complex glycoprotein alpha-1-acid glycoprotein and the Fc-fusion protein etan

44 Ribonuclease B, bovine fetuin, human alpha 1-acid glycoprotein, and the diamine oxidase (from

45 hydratase, glutathione-s-transferase omega, alpha-1-acid-glycoprotein, and phosphatidylethanolamine-

46 y, Spn was more adapted to grow on the human alpha - 1 acid glycoprotein as a sugar source with hemog

47 t alpha 1-acid glycoprotein, fetuin or human alpha 1-acid glycoprotein as acceptors together with the

48 alpha-1-Acid glycoprotein at 15 mo characterized systemi

49 enzyme measurement, alpha1-microglobulin and alpha(1)-acid glycoprotein by immunonephelometry, and se

50 (C-reactive protein concentration >5 mg/L or alpha-1-acid glycoprotein concentration >1 g/L), 2) the

51 , decreased low-grade inflammation (e.g., as alpha(1)-acid glycoprotein (FDR = 3.08 x 10(-13)) and hs

52 fused with protein A, was incubated with rat alpha 1-acid glycoprotein, fetuin or human alpha 1-acid

53 ctivity with N-acetylneuramin lactose, human alpha-1-acid glycoprotein, fetuin, colominic acid, and b

54 human IgG (for core fucosylation) and human alpha-1-acid-glycoprotein (for antenna fucosylation).

55 ns, full length heparins, and N-glycans from alpha-1-acid glycoproteins from four mammalian species.

56 Alterations in alpha 1-acid glycoprotein gene expression correlated in

57 riantennary, and tetraantennary N-glycans of alpha-1-acid glycoprotein generally containing 0 or 1 al

58 SPC(3) subfractions; 2 N-acetyl signals from alpha-1-acid glycoprotein (Glyc), GlycA, and GlycB; and

59 easured by C-reactive protein (> 5 mg/L) and alpha(1)-acid glycoprotein (> 1 g/L) before applying cut

60 Chronic systemic inflammation (plasma alpha(1)-acid glycoprotein, >1 g/dL) occurred from age 3

61 ze the glycan structures released from human alpha-1-acid glycoprotein (hAGP).

62 ter adjusting for conventional risk factors: alpha-1-acid glycoprotein (hazard ratio [HR] 1.67 per 1-

63 lls at 25.0-50.0 nM, even in the presence of alpha(1) acid glycoprotein, human serum albumin, normal

64 ycoproteins included ribonuclease B, fetuin, alpha(1)-acid glycoprotein, immunoglobulin, and thyroglo

65 ity failed to transfer sialic acid to asialo alpha(1)-acid glycoprotein, indicating that this enzyme

66 n increase in steady-state concentrations of alpha 1-acid glycoprotein messenger RNA that peaked at 1

67 The alpha 1-acid glycoprotein messenger RNA was not detected

68 ing proteins (human serum albumin or HSA and alpha-1-acid glycoprotein or AAG).

69 etinol)] and >/=1 biomarker of inflammation (alpha-1-acid glycoprotein or C-reactive protein).

70 ethylpyrocarbonate (DEPC) was used to modify alpha 1-acid glycoprotein (orosomucoid, OMD) under vario

71 elevated C-reactive protein (P = 0.0029) and alpha-1-acid glycoprotein (P = 0.0023) at baseline.

72 more, they found that C-reactive protein and alpha-1-acid glycoprotein provide important and differen

73 involved in hyper-competence, processing of alpha-1-acid glycoprotein, sensitivity against the human

74 Carbohydrate chains on alpha 1-acid glycoprotein were converted to carry alpha-

75 in-1beta, interleukin-6, corticosterone, and alpha-1 acid glycoprotein were determined in serum, and

76 the levels of cytokines, corticosterone, and alpha-1 acid glycoprotein were significantly higher in t

77 Complex N-glycans from alpha-1-acid glycoprotein were analyzed using this appro

78 ur conclusions, the glycan moieties of human alpha-1-acid glycoprotein were further analyzed using an

79 e compare the glycoforms of human and bovine alpha-1-acid glycoproteins, which exhibit highly variabl